• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

    5/16/25 4:10:00 PM ET
    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance
    Get the next $HSIC alert in real time by email

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein.

    In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Health Care industry team in the Americas, who became a member of Henry Schein's Board of Directors on May 2, 2025.

    Max Lin leads the Health Care industry team within KKR, and since joining in 2005, he has overseen a number of investments in the areas of dental services and other health care providers, medical products and equipment, and health care software and information technology. Dan Daniel has over three decades of global leadership experience in industrial and health care sectors, including 14 years as Executive Vice President at Danaher, where he oversaw multiple segments and played a key role in advancing the company's culture and business system. In connection with each of their appointments, Mr. Lin was appointed to the Nominating and Governance Committee as Vice Chair; Mr. Daniel was appointed to the Compensation Committee; and each of Mr. Lin and Mr. Daniel was appointed to the Strategic Advisory Committee.

    "We are pleased to welcome Max and Dan to the Board as we embark on this exciting next chapter for Henry Schein," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Their deep experience in health care, operations, and strategic growth will be invaluable as we continue executing on our BOLD+1 strategy and creating long-term value for our stakeholders."

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.7 billion in 2024, and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, LinkedIn.com/Company/HenrySchein, and @HenrySchein on X.

    About KKR

    KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250516439220/en/

    Investors

    Ronald N. South

    Senior Vice President and Chief Financial Officer

    ronald.south@henryschein.com

    (631) 843-5500



    Graham Stanley

    Vice President, Investor Relations and Strategic Financial Project Officer

    graham.stanley@henryschein.com

    (631) 843-5500



    Media

    Henry Schein

    Tim Vassilakos

    Executive Director, Global Corporate Communications

    timothy.vassilakos@henryschein.com

    (516) 510-0926



    KKR

    Liidia Liuksila

    media@KKR.com

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC
    $KKR

    CompanyDatePrice TargetRatingAnalyst
    Henry Schein Inc.
    $HSIC
    6/11/2026$100.00Neutral → Buy
    BTIG Research
    Henry Schein Inc.
    $HSIC
    4/16/2026Neutral
    BTIG Research
    Henry Schein Inc.
    $HSIC
    4/15/2026$100.00Buy
    Citigroup
    KKR & Co. Inc.
    $KKR
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    Henry Schein Inc.
    $HSIC
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    KKR & Co. Inc.
    $KKR
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    KKR & Co. Inc.
    $KKR
    1/14/2026$131.00Buy → Hold
    TD Cowen
    KKR & Co. Inc.
    $KKR
    12/11/2025$176.00Buy
    UBS
    More analyst ratings

    $HSIC
    $KKR
    SEC Filings

    View All

    SEC Form 11-K filed by Henry Schein Inc.

    11-K - HENRY SCHEIN INC (0001000228) (Filer)

    6/18/26 9:09:05 AM ET
    $HSIC
    Medical Specialities
    Health Care

    KKR & Co. Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    5/29/26 4:16:25 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SD filed by Henry Schein Inc.

    SD - HENRY SCHEIN INC (0001000228) (Filer)

    5/29/26 3:04:28 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KKR Announces Intra-Quarter Update

    KKR today announced income from monetization activity in excess of $900 million with respect to the period from March 31, 2026 through June 24, 2026 based on information currently available. The quarter-to-date monetization activity is made up of approximately 80% realized performance income and approximately 20% realized investment income. Based on year-to-date information available as of June 24, 2026, KKR has experienced an acceleration in its monetization activity and, in turn, an acceleration in capital returned to its clients. In Q1 2026, monetization activity (Realized Performance Income and Realized Investment Income) was $878 million, or +62% compared to the quarterly average of

    6/25/26 6:50:00 AM ET
    $KKR
    Investment Managers
    Finance

    Arctos Sports, RVX and Magellan Partner to Launch National Sports-Anchored Development Platform

    Platform’s inaugural project is Neyland Entertainment District, a transformative mixed-use district adjacent to the University of Tennessee’s Neyland Stadium Arctos, an investing business in KKR Solutions that seeks to partner with exceptional leaders in sports to help them grow and unlock their vision, today announced a strategic partnership with RVX Ventures ("RVX"), a real estate development platform specializing in mixed-use entertainment districts, and Magellan Development Group ("Magellan"), a national leader in urban mixed-use real estate, to launch a new platform targeting the rapidly growing sports-anchored development sector. This press release features multimedia. View the ful

    6/23/26 7:00:00 AM ET
    $KKR
    Investment Managers
    Finance

    KKR Commits $1.4 Billion to Aircraft Leasing with Altavair

    New commitment expands long-standing strategic partnership and builds on the success of two prior aircraft leasing portfolios KKR, a leading global investment firm, and Altavair, a leader in commercial aviation leasing and financing, today announced that KKR is making a $1.4 billion equity commitment to continue expanding its global portfolio of leased commercial aircraft in partnership with Altavair. The latest commitment builds on two prior aircraft leasing portfolios created in partnership with Altavair. The investment will primarily come from KKR's Infrastructure and Asset-Based Finance strategies. This press release features multimedia. View the full release here: https://www.busine

    6/17/26 7:00:00 AM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K was granted 2,215 shares, increasing direct ownership by 41% to 7,641 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    6/15/26 4:29:31 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Large owner Kkr Alternative Assets Llc acquired $1,523,312 worth of Class I Common Stock (65,491 units at $23.26) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    6/2/26 4:05:53 PM ET
    $KKR
    Investment Managers
    Finance

    New insider Murphy Kelly Ann claimed ownership of 34,812 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/28/26 5:01:47 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein upgraded by BTIG Research with a new price target

    BTIG Research upgraded Henry Schein from Neutral to Buy and set a new price target of $100.00

    6/11/26 8:00:35 AM ET
    $HSIC
    Medical Specialities
    Health Care

    BTIG Research initiated coverage on Henry Schein

    BTIG Research initiated coverage of Henry Schein with a rating of Neutral

    4/16/26 8:03:48 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Citigroup initiated coverage on Henry Schein with a new price target

    Citigroup initiated coverage of Henry Schein with a rating of Buy and set a new price target of $100.00

    4/15/26 8:08:55 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $691,900 worth of shares (10,000 units at $69.19) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/12/26 4:15:46 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    $HSIC
    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $KKR
    Financials

    Live finance-specific insights

    View All

    KKR Sells CIRCOR Aerospace to Parker Hannifin for $2.55 Billion

    KKR and CIRCOR International ("CIRCOR" or the "Company"), a global manufacturer of flow control products for industrial, naval, and aerospace markets, today announced the signing of a definitive agreement to sell CIRCOR Aerospace, the Company's aerospace division, to Parker Hannifin Corporation (NYSE:PH), the global leader in motion and control technologies, for $2.55 billion. Funds managed by KKR first acquired CIRCOR for $1.8 billion in 2023 and will maintain ownership of CIRCOR's Naval and Industrial businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520542910/en/ With more than 75 years of heritage in fluid contro

    5/21/26 9:15:00 AM ET
    $KKR
    $PH
    Investment Managers
    Finance
    Metal Fabrications
    Industrials

    FS KKR Capital Corp. Announces First Quarter 2026 Results and Strategic Value Enhancement Actions; Declares Second Quarter 2026 Distribution of $0.42 per share

    PHILADELPHIA and NEW YORK, May 11, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK), or the Company, today announced its financial and operating results for the quarter ended March 31, 2026 and announced certain strategic value enhancement actions, as further outlined below.  Additionally, the Company announced that its board of directors has declared a second quarter 2026 distribution of $0.42 per share. Financial and Operating Highlights for the Quarter Ended March 31, 2026(1)Net investment income of $0.42 per share, compared to $0.48 per share for the quarter ended Decemb

    5/11/26 6:51:00 AM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    KKR & Co. Inc. Reports First Quarter 2026 Results

    KKR & Co. Inc. (NYSE:KKR) today reported its first quarter 2026 results, which have been posted to the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505994009/en/ A conference call to discuss KKR's financial results will be held today, Tuesday, May 5, 2026 at 10:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center s

    5/5/26 6:50:00 AM ET
    $KKR
    Investment Managers
    Finance